Focused On-demand Library for AP-4 complex subunit beta-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y6B7

UPID:

AP4B1_HUMAN

Alternative names:

AP-4 adaptor complex subunit beta; Adaptor-related protein complex 4 subunit beta-1; Beta subunit of AP-4; Beta4-adaptin

Alternative UPACC:

Q9Y6B7; B7Z4X3; Q59EJ4; Q96CL6

Background:

AP-4 complex subunit beta-1, also known as Beta4-adaptin, plays a crucial role in vesicular transport processes. It is a component of the adaptor protein complex 4 (AP-4), which is involved in forming vesicle coats and selecting cargo for transport. This protein facilitates the movement of proteins from the trans-Golgi network to the endosomal-lysosomal system and is essential for protein sorting in neurons and epithelial cells.

Therapeutic significance:

AP-4 complex subunit beta-1 is linked to Spastic paraplegia 47, a neurodegenerative disorder. Understanding its role could lead to novel therapeutic strategies for this condition.